BioSpace News Archive

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the submission of the clinical module of the Company’s Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab (PRV-031),

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming event:

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 1,110 stock options.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Dr. John (Jack) Geltosky to the Board of Directors of Medicenna and the voting results from the Company’s annual and special meeting of shareholders held today, September 30, 2020 in Toronto (the “Meeting”).

According to Coherent Market Insights, the Latin America oncology device market is estimated to be valued at US$ 31.08 million in 2020 and is expected to exhibit a CAGR of 5.5 % over the forecast period (2020-2027). Key Trends and Analysis of the Latin America Oncology Device Market: Latin America oncology device market is expected to experience significant growth owing to the increase in prevalence of cancer in th

Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for the treatment of aged related diseases, including neuromuscular diseases, today announced a €10 million capital increase through private placement. The capital increase will be

Univfy® Inc., an artificial intelligence (AI) company whose mission is to improve fertility patients’ experience and their access to Assisted Reproductive Technologies such as IVF, announced today a partnership with Gedeon Richter, a major pharmaceutical company headquartered in Central Eastern Europe focused on women’s health,

Cannabis Science and Technology® a multimedia platform that focuses on educating the legal cannabis industry about the science and technology of analytical testing, quality control, extraction and cultivation, is excited to announce the lineup of speakers for its first Hemp Science & Technology Virtual Symposium.

Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced positive topline results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the Company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first line treatment in patients with metastatic malignant melanoma.

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its results for the first half of 2020 and provides an update on developments since the beginning of the year.